Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Biotronik’s Pulsar stents show efficacy in new studies

Biotronik’s Pulsar stents show efficacy in new studies

5th November 2013

Biotronik has shared new study data at the Cardiovascular and Interventional Radiological Society of Europe congress which underlines the benefits of its Pulsar-18 self-expanding stent system.

At the industry event in Barcelona, the company shared 24-month results from the prospective multi-centre 4EVER study, which investigated both the acute and long-term performance of four F-compatible devices in superficial femoral artery lesions.

It was found that the efficacy of Biotronik's device compared very favourably with other bare-metal stent trialled in similar clinical conditions, offering a 72.3 percent primary patency rate and a freedom from target lesion revascularisation rate of 82.7 percent.

These findings were backed up by 12-month data from the Peace registry, in which the stents showed a similarly strong performance.

Dr Alexander Uhl, vice-president for marketing at Biotronik's vascular interventions division, said: "We are very pleased that Pulsar-18 has shown such favourable results in comparison to other stents on the market."

This comes after the company showcased a number of its latest innovations at the recent Heart Rhythm Congress, which took place in Birmingham last month.ADNFCR-8000103-ID-801657221-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.